By Rob Wright, Chief Editor, Life Science Leader
Follow Me On Twitter @RfwrightLSL
If we thought investment in the biopharmaceutical industry was hot last year, then 2021 proved downright volcanic. Not only did we see plenty of “traditional” IPOs, but the special purpose acquisition corporation (SPAC) route that came into favor in 2020 also seemed to gain momentum. But the world of biopharmaceutical finance is more than what happens in the markets. For example, initiatives to halt climate change have executives reconsidering how their companies conduct business in striving for a net-zero carbon footprint. Here’s what 10 biopharmaceutical finance experts have to say as they prepare for 2022 and beyond.